drugset / Trial / NCT00547378

InSite for Over Active Bladder

NCT00547378 ↗

Phase 4 Completed 571 enrolled MedtronicNeuro
RandomizedParallel-groupOpen-labelTreatment

Summary

The purposes of this study are: 1. To provide evidence from a randomized controlled trial that InterStim Therapy provides better relief of symptoms of OAB than standard medical treatments in current use. 2. To fulfill the requirements of the FDA-mandated post-approval study of the safety of the tined lead using a minimally invasive approach.

Timeline

Start
2007-10
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darifenacin Small molecule 7.5 mg —
Comparator Darifenacin Small molecule 15 mg —
Comparator Oxybutynin Small molecule 2.5 mg Other
Comparator Oxybutynin Small molecule 3.9 mg Other
Comparator Oxybutynin Small molecule 5 mg Other
Comparator Oxybutynin Small molecule 10 mg Other
Comparator Oxybutynin Small molecule 15 mg Other
Comparator Solifenacin Small molecule 5 mg —
Comparator Solifenacin Small molecule 10 mg —
Comparator Standard Medical Therapy Unknown 4 mg —
Comparator Standard Medical Therapy Unknown 8 mg —
Comparator Tolterodine Unknown 1 mg —
Comparator Tolterodine Unknown 2 mg —
Comparator Tolterodine Unknown 4 mg —
Comparator Trospium Small molecule 20 mg —

Indications